JY
ABCL icon

Jeff Yass’s AbCellera Biologics ABCL Stock Holding History

Jeff Yass’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Sell
215,800
-318,300
-60% -$1.56M ﹤0.01% 6855
2026
Q1 		$1.86M Buy
534,100
+197,300
+59% +$710K ﹤0.01% 6338
2025
Q4 		$1.15M Buy
336,800
+38,100
+13% +$170K ﹤0.01% 6868
2025
Q3 		$1.5M Buy
298,700
+65,400
+28% +$288K ﹤0.01% 6409
2025
Q2 		$800K Buy
233,300
+56,600
+32% +$141K ﹤0.01% 8015
2025
Q1 		$394K Buy
176,700
+10,400
+6% +$29.8K ﹤0.01% 9429
2024
Q4 		$487K Buy
166,300
+70,800
+74% +$197K ﹤0.01% 8725
2024
Q3 		$248K Sell
95,500
-38,800
-29% -$108K ﹤0.01% 10026
2024
Q2 		$398K Sell
134,300
-28,900
-18% -$109K ﹤0.01% 8808
2024
Q1 		$739K Sell
163,200
-18,100
-10% -$92.4K ﹤0.01% 7587
2023
Q4 		$1.04M Buy
181,300
+33,800
+23% +$157K ﹤0.01% 6917
2023
Q3 		$679K Sell
147,500
-79,500
-35% -$484K ﹤0.01% 7520
2023
Q2 		$1.47M Buy
227,000
+97,900
+76% +$668K ﹤0.01% 5819
2023
Q1 		$973K Sell
129,100
-95,900
-43% -$871K ﹤0.01% 6889
2022
Q4 		$2.28M Buy
225,000
+99,400
+79% +$1.15M ﹤0.01% 4479
2022
Q3 		$1.24M Sell
125,600
-19,700
-14% -$216K ﹤0.01% 6070
2022
Q2 		$1.55M Buy
145,300
+80,200
+123% +$679K ﹤0.01% 5449
2022
Q1 		$635K Sell
65,100
-269,500
-81% -$2.55M ﹤0.01% 8307
2021
Q4 		$4.79M Sell
334,600
-128,000
-28% -$1.94M ﹤0.01% 3817
2021
Q3 		$9.27M Buy
462,600
+162,800
+54% +$2.88M ﹤0.01% 2977
2021
Q2 		$6.6M Buy
299,800
+275,800
+1,149% +$7.61M ﹤0.01% 3527
2021
Q1 		$815K Buy
+24,000
New +$956K ﹤0.01% 8258

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Jeff Yass's ABCL Position: Q2 2026 in Review

Jeff Yass reduced its AbCellera Biologics (ABCL) stake by 97% in Q2 2026, selling an estimated $3.57M and leaving 20,580 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #12146.

Jeff Yass first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $8.71M in Q3 2021. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Jeff Yass held 20,580 shares of AbCellera Biologics worth $162K as of Q2 2026.
  • Jeff Yass sold 729,813 AbCellera Biologics shares in Q2 2026, an estimated $3.57M.
  • AbCellera Biologics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12146 holding.
  • Jeff Yass first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
  • Jeff Yass's AbCellera Biologics position peaked at $8.71M in Q3 2021.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.